Juergen Bommer
Research Subjects
Juergen Bommer has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
E Ritz
8 shared publicationsK Andrassy
4 shared publicationsE. Ritz
Ruperto Carola University, Heidelberg
2 shared publicationsF Deinhardt
2 shared publicationsG Bommer
2 shared publicationsG Darai
2 shared publications
Latest Publications
- 26 February 2014
- Published by Springer Nature in Der Nephrologe
- Vol. 9 (2) , 117-124
Gefäßzugang zur Hämodialyse
- 26 February 2014
- Published by Springer Nature in Der Nephrologe
- Vol. 9 (2) , 117-124
Gefäßzugang zur Hämodialyse
- Open Access
- 25 April 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (7) , 2628-2633
Impact of oral calcium on mortality of dialysis patients—an underestimated risk?
Phosphate is an accepted trigger and promoter of soft tissue calcification. Today, oral calcium-containing phosphate binders are still frequently administered to reduce hyperphosphataemia in patients with reduced renal function. There is, however, increasing evidence that a positive calcium balance and elevated serum calcium concentrations may aggravate soft tissue calcification. Some recent controlled [1, 2] trials as well as recent unpublished observational evidence from Dialysis Outcome and Practice Pattern Study (DOPPS) point to increased mortality in renal patients treated with calcium-containing P binders. Unfortunately, each of these studies has some methodological limitations. Nevertheless, a recent meta-analysis documented an increased risk of myocardial infarction and stroke even in patients without kidney disease when treated with calcium supplements [3].
- 25 April 2012
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (7) , 2628-2633
Open AccessImpact of oral calcium on mortality of dialysis patients—an underestimated risk?
Phosphate is an accepted trigger and promoter of soft tissue calcification. Today, oral calcium-containing phosphate binders are still frequently administered to reduce hyperphosphataemia in patients with reduced renal function. There is, however, increasing evidence that a positive calcium balance and elevated serum calcium concentrations may aggravate soft tissue calcification. Some recent controlled [1, 2] trials as well as recent unpublished observational evidence from Dialysis Outcome and Practice Pattern Study (DOPPS) point to increased mortality in renal patients treated with calcium-containing P binders. Unfortunately, each of these studies has some methodological limitations. Nevertheless, a recent meta-analysis documented an increased risk of myocardial infarction and stroke even in patients without kidney disease when treated with calcium supplements [3].
- Open Access
- 22 February 2010
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (5) , 1703-1705
Hypothesis: calcium carbonate as phosphate binder--the fallacy of relying on serum phosphorus
Both high phosphate intake and hyperphosphataemia are associated with an increased risk of vascular calcification and other soft-tissue calcification. The dietary phosphorus content is related to the dietary protein content. It is unacceptable to reduce protein intake in order to lower serum phosphorus concentration because of the risk of malnutrition, resulting in a negative protein balance. Apart from longer or more frequent dialysis sessions, the only possible alternative is to reduce phosphorus absorption in the gut. This can be achieved either by phosphate binders or—more recently—by inhibitors of the transfer of phosphorus across the intestinal wall [12].
- 22 February 2010
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (5) , 1703-1705
Open AccessHypothesis: calcium carbonate as phosphate binder--the fallacy of relying on serum phosphorus
Both high phosphate intake and hyperphosphataemia are associated with an increased risk of vascular calcification and other soft-tissue calcification. The dietary phosphorus content is related to the dietary protein content. It is unacceptable to reduce protein intake in order to lower serum phosphorus concentration because of the risk of malnutrition, resulting in a negative protein balance. Apart from longer or more frequent dialysis sessions, the only possible alternative is to reduce phosphorus absorption in the gut. This can be achieved either by phosphate binders or—more recently—by inhibitors of the transfer of phosphorus across the intestinal wall [12].
- 13 August 2009
- Published by Springer Nature in Der Nephrologe
- Vol. 4 (5) , 401-410
Phosphathaushalt und Phosphatbindertherapie
- 13 August 2009
- Published by Springer Nature in Der Nephrologe
- Vol. 4 (5) , 401-410
Phosphathaushalt und Phosphatbindertherapie
- 1 October 2008
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 37 (10) , 545-554
DOPPS-Schätzung der Auswirkungen veränderbarer Hämodialyseverfahren auf die Überlebensrate von Dialysepatienten in Deutschland
- 1 October 2008
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 37 (10) , 545-554
DOPPS-Schätzung der Auswirkungen veränderbarer Hämodialyseverfahren auf die Überlebensrate von Dialysepatienten in Deutschland
- Open Access
- 16 July 2008
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (12) , 4002-4008
A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study
Background. The different efficacy of subcutaneous and intravenous rHuEPO results in higher doses and costs in intravenously treated patients. Darbepoetin alfa has a different pharmacokinetic profile compared to rHuEPO, and previous clinical experience suggests that subcutaneous and intravenous darbepoetin alfa may have similar efficacy.
- 16 July 2008
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (12) , 4002-4008
Open AccessA comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study
Background. The different efficacy of subcutaneous and intravenous rHuEPO results in higher doses and costs in intravenously treated patients. Darbepoetin alfa has a different pharmacokinetic profile compared to rHuEPO, and previous clinical experience suggests that subcutaneous and intravenous darbepoetin alfa may have similar efficacy.
- 1 August 2007
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 36 (8) , 342-347
Langzeittherapie mit Sevelamer
- 1 August 2007
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 36 (8) , 342-347
Langzeittherapie mit Sevelamer
- 3 March 2006
- Published by Wiley in Seminars in Dialysis
- Vol. 19 (2) , 115-119
UNRESOLVED ISSUES IN DIALYSIS: Ultrapure Dialysate: Facts and Myths
During hemodialysis, blood comes in contact with a large volume of dialysate. Since the purity of dialysate has been linked to acute and long‐term complications in hemodialysis patients, the limit of bacterial and endotoxin contamination has been reduced in recent years. Questions have been raised as to whether ultrapure dialysate is required to prevent such complications; in particular, the chronic inflammatory status frequently found in chronically hemodialyzed patients. In vivo and in vitro data suggest that cytokine stimulation in the blood depends on the concentration of bacteria or endotoxin in the dialysate and on the endotoxin permeability of the dialysis membrane. It is not proven whether ultrapure dialysate reduces significantly proinflammatory cytokine generation compared with standard dialysate within the limits of recent recommendations, if rather impermeable dialysis membranes are used. Cuprophane membranes are more permeable to cytokine‐inducing substances compared with synthetic membranes such as polysulfone and polyamide. Clinical reports have also attempted to link several acute and chronic complications of hemodialysis to dialysate purity. To date, however, there is no large randomized clinical trial demonstrating that ultrapure dialysate significantly reduces biomarkers of inflammation and other consequential putative complications, including dialysis‐related amyloidosis, erythropoietin requirement, and cardiovascular morbidity and mortality. In conclusion, based on the existing clinical data, ultrapure dialysate is recommended in the setting of suboptimal bacteriologic quality of standard dialysate and the use of permeable dialysis membranes.
- 3 March 2006
- Published by Wiley in Seminars in Dialysis
- Vol. 19 (2) , 115-119
UNRESOLVED ISSUES IN DIALYSIS: Ultrapure Dialysate: Facts and Myths
During hemodialysis, blood comes in contact with a large volume of dialysate. Since the purity of dialysate has been linked to acute and long‐term complications in hemodialysis patients, the limit of bacterial and endotoxin contamination has been reduced in recent years. Questions have been raised as to whether ultrapure dialysate is required to prevent such complications; in particular, the chronic inflammatory status frequently found in chronically hemodialyzed patients. In vivo and in vitro data suggest that cytokine stimulation in the blood depends on the concentration of bacteria or endotoxin in the dialysate and on the endotoxin permeability of the dialysis membrane. It is not proven whether ultrapure dialysate reduces significantly proinflammatory cytokine generation compared with standard dialysate within the limits of recent recommendations, if rather impermeable dialysis membranes are used. Cuprophane membranes are more permeable to cytokine‐inducing substances compared with synthetic membranes such as polysulfone and polyamide. Clinical reports have also attempted to link several acute and chronic complications of hemodialysis to dialysate purity. To date, however, there is no large randomized clinical trial demonstrating that ultrapure dialysate significantly reduces biomarkers of inflammation and other consequential putative complications, including dialysis‐related amyloidosis, erythropoietin requirement, and cardiovascular morbidity and mortality. In conclusion, based on the existing clinical data, ultrapure dialysate is recommended in the setting of suboptimal bacteriologic quality of standard dialysate and the use of permeable dialysis membranes.
- Open Access
- 31 May 2005
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (8) , 1653-1661
Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density
Background. Calcium-based phosphate binders may induce tissue calcification, and little is known about their effects on bone density. We compared the effects of a calcium with a non-calcium phosphate binder on both arterial calcification and bone density measured by computed tomography. Methods. Seventy-two adult haemodialysis patients were randomized to treatment with calcium carbonate (CC) or sevelamer (SEV) for 2 years. Electron beam CT scans were performed at baseline and at 6, 12 and 24 months. Serum phosphorus, calcium, calcium ×phosphorus product and intact parathyroid hormone (iPTH) were measured and other routine laboratory tests were also carried out. Results. The average calcium × phosphorus product was similar in the two treatment groups. However, patients receiving CC had significantly lower average iPTH (PP = 0.03) and had significantly greater increases in coronary artery (CC median 484, PP = 0.3118, between-group P = 0.0178) and aortic (CC median 610, P = 0.0003, SEV median 0, P = 0.5966, between-group P = 0.0039) calcification scores. The CC group also had a significant decrease in trabecular bone density (CC median −6%, P = 0.0049, SEV median +3%, P = 0.0296, between-group P = 0.0025). However, there was no significant difference in cortical bone density between the two groups. Conclusions. This 2 year study shows that calcium carbonate use is continuously associated with progressive arterial calcification in haemodialysis patients. In addition, it suggests that it is also associated with decreased trabecular bone density. However, this latter finding requires confirmation by a study specifically devoted to this issue.
- 31 May 2005
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (8) , 1653-1661
Open AccessTwo year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density
Background. Calcium-based phosphate binders may induce tissue calcification, and little is known about their effects on bone density. We compared the effects of a calcium with a non-calcium phosphate binder on both arterial calcification and bone density measured by computed tomography. Methods. Seventy-two adult haemodialysis patients were randomized to treatment with calcium carbonate (CC) or sevelamer (SEV) for 2 years. Electron beam CT scans were performed at baseline and at 6, 12 and 24 months. Serum phosphorus, calcium, calcium ×phosphorus product and intact parathyroid hormone (iPTH) were measured and other routine laboratory tests were also carried out. Results. The average calcium × phosphorus product was similar in the two treatment groups. However, patients receiving CC had significantly lower average iPTH (PP = 0.03) and had significantly greater increases in coronary artery (CC median 484, PP = 0.3118, between-group P = 0.0178) and aortic (CC median 610, P = 0.0003, SEV median 0, P = 0.5966, between-group P = 0.0039) calcification scores. The CC group also had a significant decrease in trabecular bone density (CC median −6%, P = 0.0049, SEV median +3%, P = 0.0296, between-group P = 0.0025). However, there was no significant difference in cortical bone density between the two groups. Conclusions. This 2 year study shows that calcium carbonate use is continuously associated with progressive arterial calcification in haemodialysis patients. In addition, it suggests that it is also associated with decreased trabecular bone density. However, this latter finding requires confirmation by a study specifically devoted to this issue.